Top MarketRank™ StocksTop MarketRank™NASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $84.38 -0.46 (-0.54%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About DexCom Stock (NASDAQ:DXCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DexCom alerts:Sign Up Key Stats Today's Range$83.89▼$86.3350-Day Range$70.31▼$84.8452-Week Range$62.34▼$142.00Volume5.13 million shsAverage Volume2.68 million shsMarket Capitalization$32.96 billionP/E Ratio50.53Dividend YieldN/APrice Target$99.29Consensus RatingModerate Buy Company OverviewDexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Read More… DexCom Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks99th Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 99% of companies evaluated by MarketBeat, and ranked 14th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth18.71% Earnings GrowthEarnings for DexCom are expected to grow by 18.71% in the coming year, from $1.71 to $2.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 50.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.80.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 50.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.34.Price to Earnings Growth RatioDexCom has a PEG Ratio of 2.00. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 15.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.25% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 5.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted2.25% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 5.68%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.88 News SentimentDexCom has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for DexCom this week, compared to 21 articles on an average week.Search Interest13 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $318,275.00 in company stock.Percentage Held by InsidersOnly 0.30% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesDexCom (NASDAQ:DXCM) shareholder returns have been decent, earning 44% in 5 yearsJanuary 19 at 5:53 AM | uk.finance.yahoo.comDexCom (NASDAQ:DXCM) Stock Rating Upgraded by Robert W. BairdJanuary 19 at 3:18 AM | americanbankingnews.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.January 21, 2025 | Crypto Swap Profits (Ad)DexCom (NASDAQ:DXCM) Upgraded at Baird R WJanuary 19 at 2:23 AM | americanbankingnews.comDexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price ComebackJanuary 17, 2025 | seekingalpha.comExpert Outlook: DexCom Through The Eyes Of 11 AnalystsJanuary 16, 2025 | benzinga.comBaird Upgrades DexCom (DXCM)January 16, 2025 | msn.comDexCom raised to outperform by BairdJanuary 16, 2025 | msn.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $77.77 at the beginning of 2025. Since then, DXCM stock has increased by 8.5% and is now trading at $84.38. View the best growth stocks for 2025 here. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Thursday, July, 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm's revenue was up 15.3% on a year-over-year basis. Read the conference call transcript. When did DexCom's stock split? Shares of DexCom split before market open on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? Top institutional shareholders of DexCom include Assenagon Asset Management S.A. (0.17%), Beacon Investment Advisory Services Inc. (0.16%), Janney Montgomery Scott LLC (0.06%) and Czech National Bank (0.02%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Steven Robert Pacelli, Jereme M Sylvain, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Bridgette P Heller, Chad Patterson and Barbara Kahn. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings7/25/2024Today1/20/2025Next Earnings (Estimated)2/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees9,600Year Founded1999Price Target and Rating Average Stock Price Target$99.29 High Stock Price Target$130.00 Low Stock Price Target$75.00 Potential Upside/Downside+17.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$1.67 Trailing P/E Ratio50.53 Forward P/E Ratio49.35 P/E Growth2Net Income$541.50 million Net Margins17.22% Pretax Margin18.81% Return on Equity31.40% Return on Assets10.58% Debt Debt-to-Equity Ratio1.23 Current Ratio2.46 Quick Ratio2.12 Sales & Book Value Annual Sales$3.62 billion Price / Sales9.10 Cash Flow$2.25 per share Price / Cash Flow37.58 Book Value$5.35 per share Price / Book15.77Miscellaneous Outstanding Shares390,600,000Free Float389,423,000Market Cap$32.96 billion OptionableOptionable Beta1.12 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:DXCM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
